| Incidence and risk factors for hypertension among HIV patients in rural Tanzania–A prospective cohort study E Rodríguez-Arbolí, K Mwamelo, AV Kalinjuma, H Furrer, C Hatz, ... PloS one 12 (3), e0172089, 2017 | 90 | 2017 |
| Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries C Récher, C Röllig, E Bérard, S Bertoli, PY Dumas, S Tavitian, M Kramer, ... Leukemia 36 (4), 913-922, 2022 | 57 | 2022 |
| Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study D Martínez-Cuadrón, JE Megías-Vericat, J Serrano, P Martínez-Sánchez, ... Blood advances 6 (4), 1278-1295, 2022 | 50 | 2022 |
| FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the … E Rodríguez-Arbolí, M Labopin, J Tischer, A Brecht, A Ganser, J Finke, ... Biology of Blood and Marrow Transplantation 26 (11), 2165-2173, 2020 | 30 | 2020 |
| Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult … C Orvain, JA Wilson, M Fang, BM Sandmaier, E Rodríguez-Arbolí, ... Haematologica 108 (2), 420, 2022 | 21 | 2022 |
| Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group C Sargas, R Ayala, MJ Larráyoz, MC Chillón, E Rodriguez-Arboli, ... Blood Cancer Journal 13 (1), 77, 2023 | 17 | 2023 |
| Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell … E Rodríguez-Arbolí, M Othus, C Orvain, LC Zarling, BM Sandmaier, ... Haematologica 108 (1), 273, 2022 | 16 | 2022 |
| Long-term outcomes after autologous versus allogeneic stem cell transplantation in molecularly-stratified patients with intermediate cytogenetic risk acute myeloid leukemia: a … E Rodríguez-Arbolí, D Martínez-Cuadrón, R Rodríguez-Veiga, ... Transplantation and cellular therapy 27 (4), 311. e1-311. e10, 2021 | 15 | 2021 |
| Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial ES Wang, GC Issa, HP Erba, JK Altman, P Montesinos, S DeBotton, ... The Lancet Oncology 25 (10), 1310-1324, 2024 | 13 | 2024 |
| SF3B1, RUNX1 and TP53 mutations significantly impact the outcome of patients with lower-risk myelodysplastic syndrome JF Falantes, FJ Márquez-Malaver, E Carrillo, MG Culebras, R Morales, ... Clinical Lymphoma Myeloma and Leukemia 22 (12), e1059-e1066, 2022 | 9 | 2022 |
| Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation E Rodriguez-Arboli, C Orvain, M Othus, RB Walter Bone marrow transplantation 57 (11), 1732-1734, 2022 | 9 | 2022 |
| Azacitidine vs. Decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA registry J Labrador, D Martínez-Cuadrón, A De La Fuente, R Rodríguez-Veiga, ... Cancers 14 (9), 2342, 2022 | 9 | 2022 |
| Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or … RB Walter, BM Sandmaier, M Othus, C Orvain, E Rodríguez-Arbolí, ... Bone marrow transplantation 58 (4), 377-385, 2023 | 8 | 2023 |
| Association between prior cytotoxic therapy, antecedent hematologic disorder, and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia C Orvain, E Rodríguez-Arbolí, M Othus, BM Sandmaier, HJ Deeg, ... Cancers 15 (2), 352, 2023 | 7 | 2023 |
| Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML C Orvain, N Ali, M Othus, E Rodríguez‐Arbolí, F Milano, CM Le, ... American Journal of Hematology 99 (5), 862-870, 2024 | 5 | 2024 |
| Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML AB Halpern, E Rodríguez-Arbolí, M Othus, KLA Garcia, MEM Percival, ... Blood Advances 7 (17), 4950-4961, 2023 | 5 | 2023 |
| Long-term impact of an educational antimicrobial stewardship program on management of patients with hematological diseases AB Guisado-Gil, M Aguilar-Guisado, G Peñalva, JA Lepe, I Espigado, ... Antibiotics 10 (2), 136, 2021 | 4 | 2021 |
| Allocation to matched related or unrelated donor results in similar clinical outcomes without increased risk of failure to proceed to transplant among patients with acute … E Rodríguez-Arbolí, FJ Márquez-Malaver, N Rodríguez-Torres, ... Biology of Blood and Marrow Transplantation 25 (1), 183-190, 2019 | 4 | 2019 |
| Targeting hedgehog signaling with glasdegib in patients with refractory sclerotic chronic GVHD: A report of two phase I/II trials E Rodríguez-Arbolí, CJ Lee, T Caballero-Velázquez, C Martínez, ... Clinical Cancer Research 29 (20), 4057-4067, 2023 | 3 | 2023 |
| Phase 1/2 trial of CLAG-M with dose-escalated mitoxantrone in combination with fractionated-dose gemtuzumab ozogamicin for newly diagnosed acute myeloid leukemia and other high … CD Godwin, E Rodríguez-Arbolí, M Othus, AB Halpern, JS Appelbaum, ... Cancers 14 (12), 2934, 2022 | 3 | 2022 |
